Advanced Search
Contact | Corporate | Help

Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older

Sponsors:
  • UCB, Inc.
  • EDEV S.À.R.L
Phases:
  • Phase III
IndicationsAcronym:
  • Epilepsy
  • Monotherapy
Age Groups:
  • Child
  • Adult
  • Senior
Gender:
Both
Names:
  • Drug: Lacosamide
  • Drug: Carbamazepine-Controlled Release (CBZ-CR)
Enrollment:
527

Additional information about NCT01465997.


SourceSolution © 2008-2012